COPY OF PAPERS ORIGINALLY FILED



SHEET 1 OF 2 SERIAL NO. ATTY. DOCKET NO. INFORMATION DISCLOSURE 10/074,575 12636-264 CITATION APPLICANT Joseph Rubinfeld GROUP Unassigned 1653 FILING DATE 02/11/02 TRADEM U.S. PATENT DOCUMENTS NAME **CLASS** SUBCLASS **FILING DATE** PATENT NO. DATE **EXAMINER'S** INITIALS 514 100 07/28/98 Ratain et al. 5,786,344 CMK FOREIGN PATENT DOCUMENTS TRANSLATION SUBCLASS CLASS PATENT NO. DATE COUNTRY **EXAMINER'S** INITIALS YES NO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Bernacki, Ralph J. et al., "In Vitro Antitumour Activity of 9-Nitro-Camptothecin as a Single Agent and in Combination with other Antitumor Drugs", Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, AAN, N.Y. ACAD. SCI., vol. 922, 2000, pp. 293-297 Karaberis, E. and D. Mourelatos, "Enhanced Cytogenetic and Antitumor Effects by 9-Nitrocamptothecin and Antineoplastics", Laboratory of Biology and Genetics, Medical School, Aristotle University, Thessaloniki, Greece, TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS, vol. 20, no. 3, 2000, pp. 141-146 Dainiak, Nicholas et al., "DNA Topoisomerase Inhibitors Block Erythropoiesis and Delay CMK Hemoglobinization In Vitro", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 138, no. 1, 1989, pp. 87-96 Drewinko, B et al., "Combination Chemo Therapy In-Vitro with Adriamycin Observations of Additive Antagonistic and Synergistic Effects When Used in 2 Drug Combinations on Cultured Lymphoma Cells", CANCER BIOCHEMISTRY BIOPHYSICS, vol. 1, no. 4, 1976, pp. 187-195 Kaufmann, Scott H."Antagonism between Camptothecin and Topoisomerase II-directed Chemotherapeutic Agents in a Human Leukemia Cell Line", CANCER RESEARCH, vol. 51, no. 4, 1991, pp. 1129-1136 MK Guichard, Sylvie et al., "Cellular Interactions of 5-Fluorouracil and the Camptothecin Analogue CPT-11 (Irinotecan) in a Human Colorectal Carcinoma Cell Line" BIOCHEMICAL PHARMACOLOGY, vol. 55, CMK no. 5, March 1, 1998, pp. 667-676 Ciesielski, M.J. et al., "Synergistic cytotoxicity, apoptosis and protein-linked DNA breakage by etoposide and camptothecin in human U87 glioma cells: dependence on tyrosine phosphorylation" JOURNAL OF CMK NEURO-ONCOLOGY, 1999, 41/3, pp. 223-234 Giovanella, B.C. et al., "Enhanced antitumor effectiveness of camptothecin (CPT) and derivatives administered by continuous infusion through scheduling and combination with DNA damaging agents." CHK PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 36, March 1991, p 391

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER

ž

£

DATE CONSIDERED

110

			_			SHEET	12 OF 2	
INFORMATION DISCLASTIVE			ATTY. DOCKET NO.	1	RIAL NO.			
CITATION O''		12636-264 10/074,575						
]	PTO-1449 nm	0 4 2002 8	APPLICANT Joseph Rubinfeld					
TRADEMINE U.S			FILING DATE 02/11/02	GR	GROUP Unassign		red /653	
	- V	HALEMAN U.S	. PATENT DOCUMENTS			·		
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE		
FOREIGN PATENT DOCUMENTS								
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
						YES	NO	
								
	OTHER DO	CUMENTS ()	Including Author, Title, Date, Pe	ertinent P	iges, Etc.)	<u> </u>		
Database WPI, Section Ch, Week 199309, Derwent Publications Ltd., London, GB, Class B02, AN 071029								
			·					
CMK	Takimoto, Chris H. and Susan G. Arbuck, "The Camptothecins", CANCER CHEMOTHERAPY AND BIOTHERAPY, 1996, Chabner, Philadelphia, pp. 463-484							
						•		
						<u></u>		
	 				 			
EXAMINER	Ch		DATE CONSIDERED	6/10/	4			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER

4

ų.